Literature DB >> 9747819

Sphincter preservation in rectal cancer with preoperative radiation therapy and coloanal anastomosis: long term follow-up.

R Wagman1, B D Minsky, A M Cohen, J G Guillem, P P Paty.   

Abstract

BACKGROUND: To determine if preoperative radiation therapy allows sphincter preservation in the treatment of rectal cancer.
METHODS: Thirty six patients with the diagnosis of invasive, resectable, primary adenocarcinoma of the rectum limited to the pelvis were enrolled on a Phase I/II trial of preoperative radiation therapy plus low anterior resection/coloanal anastomosis. By preoperative assessment, all patients had invasive tumors (5,T2; 31,T3) involving the distal half of the rectum and clinically required an abdominoperineal resection. The median tumor size was 3.8 cm [range: 1.5-7 cm] and the median distance from the anal verge was 4 cm [range: 3-7 cm]. The whole pelvis received 46.80 Gy followed by a 3.60 Gy boost to the primary tumor bed. The median follow-up was 56 months [range: 4-121 months].
RESULTS: Of the 35 patients who underwent resection, 5 (14%) had a complete pathologic response and 27 (77%) were able to successfully undergo a low anterior resection/coloanal anastomosis. The incidence of local failure was crude: 17% and 5-year actuarial: 21%. The 5-year actuarial survival was 64%. Analysis of sphincter function using a previously published scale was performed at the time of last follow-up in the 27 patients who underwent a low anterior resection/coloanal anastomosis. Function was good or excellent in 85%. The median number of bowel movements/day was 2 (range: 0-8).
CONCLUSIONS: Our data suggest that preoperative radiation therapy allows sphincter preservation in 77% of selected patients who would otherwise require an abdominoperineal resection, and 85% have good to excellent sphincter function. Given the moderate local failure rate, we now routinely use preoperative combined modality therapy plus postoperative chemotherapy for patients with clinical T3 disease.

Entities:  

Mesh:

Year:  1998        PMID: 9747819     DOI: 10.1016/s0360-3016(98)00180-1

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  48 in total

1.  Colorectal Cancer OncoGuia.

Authors:  Paula Manchon Walsh; Josep M Borràs; Tàrsila Ferro; Josep Alfons Espinàs
Journal:  Clin Transl Oncol       Date:  2010-03       Impact factor: 3.405

2.  Diffusion-weighted magnetic resonance imaging for prediction of tumor response to neoadjuvant chemoradiotherapy using irinotecan plus S-1 for rectal cancer.

Authors:  Hiroshi Doi; Naohito Beppu; Takashi Kato; Masashi Noda; Hidenori Yanagi; Naohiro Tomita; Norihiko Kamikonya; Shozo Hirota
Journal:  Mol Clin Oncol       Date:  2015-07-21

3.  Neoadjuvant radiochemotherapy for patients with locally advanced rectal cancer leads to impairment of the anal sphincter.

Authors:  Joerg Theisen; Werner K-H Kauer; Hjalmar Nekarda; Ludwig Schmid; Hubert J Stein; Joerg-Ruediger Siewert
Journal:  J Gastrointest Surg       Date:  2006-02       Impact factor: 3.452

Review 4.  [Neoadjuvant radiochemotherapy for rectal cancer].

Authors:  W Hohenberger; G Lahmer; R Fietkau; R S Croner; S Merkel; J Göhl; R Sauer
Journal:  Chirurg       Date:  2009-04       Impact factor: 0.955

5.  Prognostic value of rsf-1/hbxap in human solid tumors: a meta-analysis of cohort studies.

Authors:  Jiayuan Wu; Liren Hu; Fenping Wu; Taiping He
Journal:  Int J Clin Exp Med       Date:  2015-02-15

6.  Effects of preoperative chemoradiotherapy on anal sphincter functions and quality of life in rectal cancer patients.

Authors:  Aras Emre Canda; Cem Terzi; Ilknur B Gorken; Ilhan Oztop; Selman Sokmen; Mehmet Fuzun
Journal:  Int J Colorectal Dis       Date:  2009-09-26       Impact factor: 2.571

Review 7.  Intersphincteric Resection Pushing the Envelope for Sphincter Preservation.

Authors:  Quentin Denost; Eric Rullier
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

8.  Radiation dose intensification in pre-operative chemo-radiotherapy for locally advanced rectal cancer.

Authors:  F Alongi; S Fersino; R Mazzola; A Fiorentino; N Giaj-Levra; F Ricchetti; R Ruggieri; G Di Paola; M Cirillo; S Gori; M Salgarello; G Zamboni; G Ruffo
Journal:  Clin Transl Oncol       Date:  2016-06-07       Impact factor: 3.405

9.  SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents a therapeutic target with high potential.

Authors:  Yu-Feng Tian; Tzu-Ju Chen; Ching-Yih Lin; Li-Tzong Chen; Li-Ching Lin; Chung-Hsi Hsing; Sung-Wei Lee; Ming-Jen Sheu; Hao-Hsien Lee; Yow-Ling Shiue; Hsuan-Ying Huang; Hsin-Yi Pan; Chien-Feng Li; Shang-Hung Chen
Journal:  Tumour Biol       Date:  2013-01-18

10.  Overexpression of ANXA1 confers independent negative prognostic impact in rectal cancers receiving concurrent chemoradiotherapy.

Authors:  Ming-Jen Sheu; Chien-Feng Li; Ching-Yih Lin; Sung-Wei Lee; Li-Ching Lin; Tzu-Ju Chen; Li-Jung Ma
Journal:  Tumour Biol       Date:  2014-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.